Venus Remedies Limited has informed the Exchange regarding Board meeting held on August 01, 2025.

Going-concern doubtEmphasis of matterRevenue growth above 20%Profit growth above 25%EBITDA margin expansionResults View source PDF Explain this filing

VENUSREM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.0%Reaction day

₹530.00

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.5%-2.5% vs market

Pharmaceuticals peers, median of 150sector+0.7%-2.7% vs sector

On the reaction day the stock moved 2.5 pts less than Nifty Microcap 250 and 2.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.0+0.5-2.5+0.7-2.7

Next day

-4.0+0.2-4.1-0.2-3.8

-5.9-0.9-5.0-1.9-4.0

-7.5-1.2-6.3-1.1-6.4

-9.4-2.0-7.3-2.0-7.4

-10.6-1.9-8.7-1.6-9.0

-8.8-1.2-7.6-1.0-7.8

15d

-9.4-1.5-7.9-2.3-7.1

-12.3+0.0-12.3-1.8-10.5

-10.1-0.5-9.6-3.6-6.5

-15.9+1.3-17.1-3.1-12.8

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Venus Remedies reported strong Q1 FY26 results, with consolidated revenue from operations rising to ₹131.90 Cr from ₹108.61 Cr in Q1 FY25, a growth of about 21%. Consolidated net profit jumped sharply to ₹9.60 Cr from just ₹1.22 Cr a year ago, while EBITDA grew to ₹18.80 Cr. On a standalone basis, revenue climbed to ₹131.85 Cr (vs ₹105.86 Cr) and net profit rose to ₹11.69 Cr (vs ₹4.45 Cr), with EPS of ₹8.76. The auditor flagged two emphasis-of-matter points: German subsidiary Venus Pharma GmbH's net worth has turned negative by ₹295.40 lakhs, raising a going-concern doubt, and ₹2,859.72 lakhs of share application money for that subsidiary remains pending allotment due to German law requirements.

Likely market impact

Strong quarterly performance with double-digit revenue growth and a near 7x jump in consolidated net profit is positive for shareholders. However, the auditor's emphasis on the German subsidiary's negative net worth and large unrecovered share application money represents a real risk overhang on the stock.